Nuclivision

Executive Summary

Nuclivision is a Belgian medical technology company founded in 2016 and headquartered in Leuven, specializing in software solutions for nuclear medicine, particularly PET imaging. Its flagship product, NUCLARITY®, is designed to optimize imaging workflows, aiming to reduce patient radiation exposure, improve operational efficiency, and lower costs for healthcare providers. By addressing key pain points in nuclear medicine—such as lengthy imaging times and high radiation doses—Nuclivision seeks to make PET imaging faster, safer, and more accessible. The company operates in the diagnostics and medical devices sectors, targeting hospitals and imaging centers that seek to enhance throughput while maintaining image quality. As a private, early-stage company with limited publicly available financial data, Nuclivision's progress relies on clinical validation and commercial adoption. The growing demand for advanced diagnostic tools and emphasis on patient safety position the company favorably, though execution risks remain typical for a medtech startup. Its focus on software-based innovation differentiates it from hardware-centric competitors, potentially enabling scalable deployment across existing PET scanners.

Upcoming Catalysts (preview)

• Q3 2026CE Mark Certification for NUCLARITY®70% success